Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | LATS1 | O95835 | 5/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 5/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249921 | 0.87 | KIF11 (0.38) | KIF11S1PR1S1PR3PDGFRBPDGFRA | |
| SCHEMBL26828845 | 0.81 | HPGDS (0.33) | HPGDSTRPV1 | |
| SCHEMBL19802020 | 0.80 | HPGDS (0.33) | HPGDSTRPV1 | |
| SCHEMBL418110 | 0.78 | CYP1A2 (0.57) | PDGFRBPDGFRATRPV1MAPTHPGD | |
| SCHEMBL1695518 | 0.78 | TRPV1 (0.40) | HPGDSTRPV1NPC1MAPTHPGD | |
| SCHEMBL25878168 | 0.78 | CLK1 (0.45) | KIF11LATS1LATS2HTTCLK1 | |
| SCHEMBL4548632 | 0.76 | SCN10A (0.42) | TRPV1NPC1MAPTHPGDRAB9A | |
| SCHEMBL7994921 | 0.76 | CYP1A2 (0.59) | HPGDSPDGFRBPDGFRALATS1CYP2A6 | |
| SCHEMBL12416706 | 0.76 | ALDH1A1 (0.47) | TRPV1TSHRNPSR1CYP2A6 | |
| SCHEMBL19386405 | 0.75 | HPGDS (0.40) | HPGDSPDGFRBPDGFRALATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20180022730-A1 | SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-9844539-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | disclosed |
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | HPGDS 2553/4885KIF11 3394/4885S1PR1 4710/4885 |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | HPGDS 1022/4885KIF11 3669/4885S1PR1 2734/4885 |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | HPGDS 2678/4885KIF11 2019/4885S1PR1 318/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | HPGDS 2524/4885KIF11 1361/4885S1PR1 1431/4885 |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HPGDS 949/4885KIF11 1646/4885S1PR1 2957/4885 |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | HPGDS 3195/4885KIF11 2483/4885S1PR1 2082/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | HPGDS 2524/4885KIF11 1361/4885S1PR1 1431/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | HPGDS 4494/4885KIF11 2741/4885S1PR1 270/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | HPGDS 3195/4885KIF11 2483/4885S1PR1 2082/4885 |
| US-20230174531-A1 | SATURATED SPIROCYCLICS AS ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | HPGDS 2072/4885KIF11 2614/4885S1PR1 161/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HPGDS 949/4885KIF11 1646/4885S1PR1 2957/4885 |
| US-20180022730-A1 | SMALL-MOLECULE INHIBITORS TARGETING DISCOIDIN DOMAIN RECEPTOR 1 AND USES THEREOF | DDR1, DDR2, DDRGK1 | HPGDS 1535/4885KIF11 4797/4885S1PR1 1310/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HPGDS 949/4885KIF11 1646/4885S1PR1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.